Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

Daillère, Romain; Routy, Bertrand; Goubet, Anne-Gaëlle; Cogdill, Alexandria P.; Ferrere, Gladys; Silva, Carolina Alves-Costa; Fluckiger, Aurélie; Ly, Pierre; Haddad, Yacine; Pizzato, Eugénie; Thelemaque, Cassandra; Fidelle, Marine; Mazzenga, Marine; Roberti, María Paula; Melenotte, Cléa; Liu, Peng; Terrisse, Safae; Kepp, Oliver; Kroemer, Guido; Zitvogel, Laurence; Derosa, Lisa

doi:10.1080/2162402x.2020.1794423

Cited by 9 publications

(7 citation statements)

References 85 publications

(170 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The microbiome is a hot topic in the healthcare industry. The microbiome has strong effects on obesity 23 , immunity 24 , vaccine efficacy 25 , and immune checkpoint inhibitors in cancer 26 . Many probiotics and prebiotics have been developed and are under development; however, the regulation of the sensing mechanisms is not well elucidated.…”

Section: Discussionmentioning

confidence: 99%

Methylated (−)-epigallocatechin 3-O-gallate potentiates the effect of split vaccine accompanied with upregulation of Toll-like receptor 5

Kumazoe

Takamatsu

Horie

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Split-virus vaccine serves as a major countermeasure against influenza virus, but its effectiveness and protective action are not complete. We previously demonstrated the effect of Benifuuki, a green tea cultivar in Japan, on enhancing the split-virus vaccine–elicited immune response. However, little is known about the detail mechanisms. Here, we show that EGCG3”Me intake significantly potentiated the vaccine-elicited hemagglutination inhibition titer increase. Flow cytometry analysis revealed the increased Toll-like receptor 5 (TLR5) expression after EGCG3”Me treatment in lamina propria dendritic cells (LPDCs) and macrophages, which play crucial roles in the humoral immune system. TLR5 expression correlated with the level of interleukin-6 (IL-6)/C–C chemokine type receptor 5, which are important mediators of the humoral immunity. Taken together, In vivo and ex vivo studies showed that EGCG3”Me potentiated the split-virus vaccine–elicited immune response accompanied with the upregulation of TLR5 in intestine and splenocyte macrophages.

show abstract

Section: Discussionmentioning

confidence: 99%

Methylated (−)-epigallocatechin 3-O-gallate potentiates the effect of split vaccine accompanied with upregulation of Toll-like receptor 5

Kumazoe

Takamatsu

Horie

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The important role of the gut microbiome determines the effect of anticancer therapy including immunogenic chemotherapy and immune checkpoint blocker [48]. Tumorigenesis is sometimes combined with immunosuppression which decreases the anticancer immunological defense activated in the host [49].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…They have as well discussed preclinical and clinical investigations that have enhanced our understanding about the roles and the mechanisms through which microbiome influences the response to treatment with immune checkpoint inhibitors [51]. It seems that a variable gut microbiota supports therapeutic anticancer responses, while a microbiome composition that lacks immunostimulatory bacteria or contains excessive immunosuppressive species results in treatment failure [48]. T cell immunoglobulin together with mucin domain-containing protein-3 (Tim-3) are immune checkpoint molecules and targets for anti-cancer therapy [52].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

New Horizon on Gut Microbiome and Cancers: Recent Information on Pathogenesis and Treatment

Fukui¹

2022

AJIM

View full text Add to dashboard Cite

An increasing number of studies have suggested that gut microbiota is closely related to tumor pathogenesis and their treatments. Among cancers, there have been many reports concerning gut microbiome and colon cancer (CRC), where microbial dysbiosis with depressing the population of "benign microbes" and increasing "harmful microbes" can lead to chronic enterocolitis and cancer development with progression. In addition, gut dysbiosis may change the metabolism of bile acids promoting CRC, which would offer a potential preventive therapeutic change in CRC by regulating gut microbiome and bile acid metabolism. Recently, SARS-CoV-2 impacts the gut microbiota, and the effects will have on CRC carcinogenesis. Obesity is estimated as an important factor that increases the risk of CRC. There has been accumulating evidence that the modulation of the gut microbiota composition by probiotics, prebiotics, and diets protects patients with CRC. Hepatocellular carcinoma (HCC) as the third leading cause of worldwide cancer mortality. Development of HCC in cirrhotic patients is related to changes in intestinal microbiome, including an escalation of dysbiosis and reduced bacterial richness. The species richness of fecal microbiota of hepatitis B-HCC patients was much high. The alterations of fecal microbiome may affect the process of Helicobacter pylori (H. pylori)-related progression of gastric lesion. Patients with gastric cancer have distinct microbiome in the stomach with lower biodiversity. Some bacteria from gastric microbiome are potentially carcinogenic as they are changed in gastric cancer. Patients with pancreas cancer and cholangiocarcinoma have also been related to gut dysbiosis. Other malignancies outside the gut like breast cancer (BC) might be related to gut microbiome as they might affect through metabolic, neural, and endocrine signal and immune function in the occurrence and progression of BC. Finally, cancer cachexia might be also associated with gut dysbiosis as it is closely related to bile acids (BA) metabolism regulation. The effects and side effects by variable cancer therapies such as chemotherapy, radiotherapy and also immunotherapy may be reconsidered from gut microbiome.

show abstract

“…The gut microbiota also plays a role in anticancer responses: a dysbiotic microbiota composition lacking immunostimulatory bacteria or containing immunosuppressive species causes treatment failure [41]. The gut microbiome was recently recognized to influence the effectiveness of PD-1-based anticancer immunotherapy, and the authors concluded that healthy gut flora is a determinant of the anticancer response [42].…”

Section: Liver Cancer Pathogenesis and Immunological Tolerance As The Basis For Hcc Developmentmentioning

confidence: 99%

The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma

Montella

Sarno

Ambrosino

et al. 2021

Cells

View full text Add to dashboard Cite

In contrast to several tumors whose prognoses are radically affected by novel immunotherapeutic approaches and/or targeted therapies, the outcomes of advanced hepatocellular carcinoma (HCC) remain poor. The underlying cirrhosis that is frequently associated with it complicates medical treatment and often determines survival. The landscape of HCC treatment had included sorafenib as the only drug available for ten years, until 2018, when lenvatinib was approved for treatment. The second-line systemic treatments available for hepatocellular carcinoma include regorafenib, cabozantinib, ramucirumab, and, more recently, immune checkpoint inhibitors. However, the median survival remains below 15 months. The results obtained in clinics should be interpreted whilst considering the peculiar role of the liver as an immune organ. A healthy liver microenvironment ordinarily experiences stimulation by gut-derived antigens. This setup elucidates the response to chronic inflammation and the altered balance between tolerance and immune response in HCC development. This paper provides an overview of the mechanisms involved in HCC pathogenesis, with a special focus on the immune implications, along with current and future clinical perspectives.

show abstract

Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

Cited by 9 publications

References 85 publications

Methylated (−)-epigallocatechin 3-O-gallate potentiates the effect of split vaccine accompanied with upregulation of Toll-like receptor 5

Methylated (−)-epigallocatechin 3-O-gallate potentiates the effect of split vaccine accompanied with upregulation of Toll-like receptor 5

New Horizon on Gut Microbiome and Cancers: Recent Information on Pathogenesis and Treatment

The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma

Contact Info

Product

Resources

About